Dopamine

Denovo Biopharma Announces a Major Breakthrough in Treatment‑Resistant Depression with Precision Medicine

Retrieved on: 
Tuesday, April 9, 2024

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).

Key Points: 
  • Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its biomarker‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).
  • More than 23 million people in the U.S. alone suffer from major depressive disorder (MDD).
  • TRD remains a highly unmet medical need indication as there are few approved pharmacological agents for TRD and overall, outcomes remain poor.
  • Using its unique big data based Denovo Genomic Marker (DGM™) biomarker platform, Denovo discovered a novel genetic biomarker, termed DGM4™, which was hypothesized to predict liafensine’s efficacy in TRD patients.

Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial

Retrieved on: 
Wednesday, March 13, 2024

The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.

Key Points: 
  • The approval, previously announced on February 23, 2024, allows Clearmind to start its pioneering clinical trial.
  • The clinical trial is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic study of CMND-100 in healthy volunteers and AUD subjects.
  • The Clearmind team has been working tirelessly on the research and development of a novel treatment to the global epidemic of alcoholism.
  • We are eager to continue our work with patients in need of help,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Olfactive Biosolutions Files Patent to Repurpose Food Molecules to Safely, Inexpensively Regulate Blood Pressure

Retrieved on: 
Tuesday, April 2, 2024

The Protenx patent also allows for administration including but not limited to topically, sublingual lozenges, inhaled or administered in multiple other ways.

Key Points: 
  • The Protenx patent also allows for administration including but not limited to topically, sublingual lozenges, inhaled or administered in multiple other ways.
  • “We are replacing prescription pharmaceuticals with common food molecules, creating a new, inexpensive, easy-to-digest category of health care solutions,” said Nils Lommerin, President and CEO of Olfactive Biosolutions.
  • “We believe regulating blood pressure is an important aspect of people’s health, and we are excited to have filed a new patent for Protenx to safely and inexpensively replace pharmaceuticals that currently control blood pressure in millions of people worldwide.
  • “Adding the patent for controlling blood pressure to the Protenx products for weight loss, with new products for other conditions to come, establishes us as the leader in the food as pharmaceuticals category of health care.

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

Retrieved on: 
Thursday, March 21, 2024

BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson's Disease is today presenting their latest data in Parkinson's Disease, at the 23rd Congress of the Japanese Society for Regenerative Medicine, in Niigata, Japan.

Key Points: 
  • Parkinson's Disease is the second most common neurodegenerative disease, caused by the progressive loss of neurons in the midbrain and other brain regions.
  • Affecting 10 million people worldwide, it is a debilitating disease and there is an urgent unmet need as only symptomatic treatment is currently available.
  • Symptoms usually appear when between 60-80% of dopaminergic neurons are already lost, so a regenerative medicine approach that can replace these neurons holds great potential.
  • The microtissue format has many benefits, including better reproducibility and a better-quality control as batch release is based on mechanism of action relevant dopamine quantification" explains Maxime Feyeux, Chief Scientific Officer, TreeFrog Therapeutics.

China Medical University Hospital's New Tech "AI-aided Diagnostic System" Assist to Diagnose Freezing of Gait (Parkinson's Disease) in Just 30 Minutes

Retrieved on: 
Thursday, March 21, 2024

Early stages of PD gait disorders require detailed neurological examinations and tests for accurate diagnosis.

Key Points: 
  • Early stages of PD gait disorders require detailed neurological examinations and tests for accurate diagnosis.
  • China Medical University Hospital (CMUH) AI Center and the Department of Neurology have utilized AI auxiliary tools to analyze the patient's gait videos and walkway pressure data utilizing the AI algorithms, to construct an "AI-aided diagnostic system for freezing of gait."
  • Noticeable symptoms of the early onset include limb tremors, slowness of movement, muscle and joint stiffness, hunched back, scoliosis, etc.
  • This system is particularly beneficial for patients in rural areas, reducing the need for hospital visits:
    Time-saving: instantly assist in the diagnosis within 30 minutes of completion of the freezing of gait examination.

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

Retrieved on: 
Thursday, March 21, 2024

BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with its lead program in Parkinson's Disease is today presenting their latest data in Parkinson's Disease, at the 23rd Congress of the Japanese Society for Regenerative Medicine, in Niigata, Japan.

Key Points: 
  • Parkinson's Disease is the second most common neurodegenerative disease, caused by the progressive loss of neurons in the midbrain and other brain regions.
  • Affecting 10 million people worldwide, it is a debilitating disease and there is an urgent unmet need as only symptomatic treatment is currently available.
  • Symptoms usually appear when between 60-80% of dopaminergic neurons are already lost, so a regenerative medicine approach that can replace these neurons holds great potential.
  • The microtissue format has many benefits, including better reproducibility and a better-quality control as batch release is based on mechanism of action relevant dopamine quantification" explains Maxime Feyeux, Chief Scientific Officer, TreeFrog Therapeutics.

Food and Beverage Name-branding Agency Eat My Words Presents "The Love Your Name Award" at the Natural Products Expo West Show

Retrieved on: 
Wednesday, March 20, 2024

SAN DIEGO, March 20, 2024 /PRNewswire/ -- Boutique naming firm Eat My Words ( www.eatmywords.com ) recently presented the "The Love Your Name Award" to 10 companies at the Expo West Natural Foods Show.

Key Points: 
  • SAN DIEGO, March 20, 2024 /PRNewswire/ -- Boutique naming firm Eat My Words ( www.eatmywords.com ) recently presented the "The Love Your Name Award" to 10 companies at the Expo West Natural Foods Show.
  • If you have a name that people love before they even try the product, you're golden," said Alexandra Watkins, the aptly named "Big Cheese" of Eat My Words.
  • "When someone sees a brand name that makes them break out in a grin, their brain releases positive neurotransmitters, including dopamine, endorphins, and serotonin.
  • These 10 names were determined to be the cream of the crop of the more than 3,000 brands exhibiting at Expo West.

Health Direct Introduces AminoMind, The First-Of-Its-Kind Nootropic Collagen

Retrieved on: 
Thursday, March 14, 2024

IRVINE, Calif., March 14, 2024 /PRNewswire/ -- Health Direct, makers of AminoSculpt Liquid Collagen, has released the first-ever nootropic collagen, AminoMind. This new form of liquid collagen contains the clinically documented dosage of Brain-derived Neurotropic Factor (BDNF) building nutrients. BDNF creates new brain cells (neurogenesis) and supports new neural pathways and adaptation (neuroplasticity.)

Key Points: 
  • IRVINE, Calif., March 14, 2024 /PRNewswire/ -- Health Direct, makers of AminoSculpt Liquid Collagen, has released the first-ever nootropic collagen, AminoMind.
  • This new form of liquid collagen contains the clinically documented dosage of Brain-derived Neurotropic Factor (BDNF) building nutrients.
  • CollaBrain's dipeptides are the only collagen clinically shown to improve brain health and support BDNF production.
  • It's about supporting your brain's structure," says Jim Caras, founder of Health Direct, "Imagine pouring very expensive water into a bucket with holes.

United Breast Cancer Foundation Uplifts Those Facing Breast Cancer at Huntington Station Spring Pink Bag Event

Retrieved on: 
Monday, March 11, 2024

HUNTINGTON STATION, N.Y., March 11, 2024 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) is excited to announce the highly anticipated return of its Spring Pink Bag Event to its Huntington Station headquarters. Taking place from Saturday, March 23rd to Wednesday, March 27th, 2024, this individualized, free "shopping" event promises to fill hearts and Pink Bags with a touch of spring cheer for breast cancer patients and survivors.

Key Points: 
  • HUNTINGTON STATION, N.Y., March 11, 2024 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) is excited to announce the highly anticipated return of its Spring Pink Bag Event to its Huntington Station headquarters.
  • Embrace the spirit of renewal and rejuvenation by joining UBCF for the Spring Pink Bag Event.
  • UBCF is committed to supporting individuals facing this challenge, and the Spring Pink Bag Event aims to alleviate some burdens and bring joy and comfort to individuals facing breast cancer.
  • Learn more about UBCF's Spring Pink Bag Event and submit your eligibility form today at https://www.ubcf.org/march-2024-ny-pbe/

Why cocaine is considered performance-enhancing for athletes, and why it matters when the athlete took it

Retrieved on: 
Wednesday, April 3, 2024

Last year a Melbourne Demons player, Joel Smith, and two Sydney Swans AFLW players were caught with cocaine.

Key Points: 
  • Last year a Melbourne Demons player, Joel Smith, and two Sydney Swans AFLW players were caught with cocaine.
  • So how is cocaine considered performance enhancing, and why does it matter when they took it?

What is cocaine and is it performance enhancing?

  • Once consumed, cocaine increases the level of a chemical in the brain called dopamine – a messenger molecular that is associated with pleasure and reward.
  • A surge in dopamine is responsible for feelings of euphoria, heightened energy, and alertness, which makes cocaine highly sought-after for recreational purposes.
  • When used during sport, cocaine is considered to have performance enhancing effects and is prohibited under the World Anti-Doping Code and listed under the Substances of Abuse Category.

Recreational (out of competition) vs performancing-enhancing (in-competition) use

  • As a result, instead of a ban from competing, the court gave them 12-month conditional release orders, with no convictions recorded.
  • Under the AFL’s anti-doping code, a finding of using cocaine for performance enhancement could come with a four-year ban.
  • If he was found to have used it for only recreational purposes, not on game day, the ban would instead just be one or three months.

Can urine testing determine when someone took cocaine?

  • Intact cocaine can remain detectable in urine for periods up to 15 days, and BZE can be detectable up to 25 days.
  • To determine the date of cocaine use, the concentration of intact drug in the athlete’s urine, and possibly the BZE concentration, need to be considered.
  • But there are fundamental flaws in making these comparisons to determine when an athlete took cocaine.

Why is cocaine still considered performance-enhancing?


While it’s unlikely an athlete can genuinely get an athletic edge on their rivals by taking cocaine, it is still on Sports Integrity Australia’s Prohibited List because “all prohibited substances are added to the Prohibited List because they meet two of the three following criteria”:
Athletes really are risking a lot for minimal (if any) athletic reward when they take cocaine – not just the health risks, but the possibility of getting caught with a substance that is extremely unlikely to improve their on-field performances.
Nial Wheate has previously appeared as an expert witness for an athlete accused by Sport Integrity Australia of in-competition cocaine use. Shoohb Alassadi does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.